Table 2.

Frequency of genomic variants and/or gene fusions among FNA samples from Afirma GSC suspicious Bethesda III/IV nodules and Bethesda V/VI nodules

	No. of alterations identified	Expanded XA panel fusions
		0	1	2
BRAF V600E Classifier + expanded XA panel variants	0	9681	1154	6
	1	7190	30	0
	2	219	1	0
	3	5	0	0
XA intended use cohort					18286

Among Afirma Xpression Atlas (XA) intended use cohort (n = 18 286) (Afirma GSC suspicious Bethesda III/IV nodules [n = 16 594] and Bethesda V/VI nodules [n = 1692]), 45.6% of samples (7190 + 1154) had precisely 1 alteration (variant or fusion) identified. More than 1 alteration was seen in 1.4% of the target population (219 + 5 + 30 + 1 + 6). Six samples had 2 fusions identified.

Abbreviations: FNA, fine-needle aspiration; GSC, Genomic Sequencing Classifier.